Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29161121 | 0.87 | ALDH1A1 (0.52) | ALDH1A1TSHRTHRBTDP1HSD17B10 | |
| SCHEMBL27550157 | 0.83 | ALDH1A1 (0.41) | ALDH1A1TSHRTHRB | |
| SCHEMBL29235995 | 0.83 | ALDH1A1 (0.71) | ALDH1A1TSHRMGAMGAASI | |
| SCHEMBL2584395 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TSHRTHRBTDP1HSD17B10 | |
| SCHEMBL2528102 | 0.80 | ALDH1A1 (0.52) | ALDH1A1TSHRTHRBTDP1HSD17B10 | |
| SCHEMBL5672798 | 0.78 | ALDH1A1 (0.44) | ALDH1A1TSHRTHRBTDP1 | |
| SCHEMBL3446223 | 0.78 | ALDH1A1 (0.44) | ALDH1A1TSHRTHRBTDP1 | |
| Methacrylic Acid SCHEMBL3260597 | 0.77 | ALDH1A1 (0.42) | ALDH1A1MGAMGAASIMGAM2 | |
| SCHEMBL371452 | 0.77 | ALDH1A1 (0.55) | ALDH1A1TSHRTHRBTDP1HSD17B10 | |
| SCHEMBL27495821 | 0.77 | ALDH1A1 (0.42) | ALDH1A1MGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024168360-A2 | ENHANCED EMISSIVITY OF POLYMER COMPOSITIONS FOR RADIATIVE COOLING APPLICATIONS | FUTUREWEI TECHNOLOGIES, INC. (US) | 2024-08-15 | — | — | WO | claimed |
| WO-2022228846-A1 | METHOD FOR PRODUCING A TERMINAL-FUNCTIONAL POLYMER | BASF SE (DE) | 2022-11-03 | — | — | WO | claimed |
| CN-113831794-A | Basalt flake acrylic resin composite modified polyvinylidene fluoride coating | 华麟海(海南)新材料科技有限公司 | 2021-12-24 | — | — | CN | claimed |
| CN-111057422-A | Polyvinylidene fluoride coating and preparation method thereof | 中昊北方涂料工业研究设计院有限公司 | 2020-04-24 | — | — | CN | claimed |
| EP-4395749-B1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING GUANFACINE AND A MONO-CARBOXYLIC ACID | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2025-11-19 | — | — | EP | disclosed |
| EP-4615884-A1 | PROCESS FOR FORMING AN AQUEOUS DISPERSION OF COPOLYMERS, AN ADHESIVE COMPOSITION INCLUDING SUCH COPOLYMERS, A FILM OR AN ARTICLE COMPRISING THE SAME, AND A METHOD OF COATING A SUBSTRATE | Wacker Chemie AG (DE) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025127152-A1 | METAL OXIDE PARTICLES HAVING IMPROVED HYDROPHOBICITY, HIGHLY CONCENTRATED METAL OXIDE SOL, AND METHODS FOR PRODUCING SAME | 日産化学株式会社 | 2025-06-19 | — | — | WO | disclosed |
| EP-3996692-B1 | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING AN ACTIVE AGENT-CONTAINING LAYER COMPRISING A SILICONE-CONTAINING POLYMER AND A SKIN CONTACT LAYER COMPRISING A SILICONE GEL ADHESIVE | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2025-06-11 | — | — | EP | disclosed |
| US-12214088-B2 | Transdermal therapeutic system for the transdermal administration of guanfacine comprising at least one additive | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2025-02-04 | — | — | US | disclosed |
| US-12168074-B2 | Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone polymer | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2024-12-17 | — | — | US | disclosed |
| CN-111465392-B | Transdermal therapeutic system for transdermal administration of guanfacine comprising a silicone polymer | 罗曼治疗系统股份公司 | 2024-12-17 | — | — | CN | disclosed |
| US-20240400825-A1 | RESIN COMPOSITION, CURED PRODUCT THEREOF, LAMINATE USING SAME, ELECTROSTATIC CHUCK, AND PLASMA PROCESSING EQUIPMENT | TORAY INDUSTRIES, INC. (JP) | 2024-12-05 | — | — | US | disclosed |
| EP-1209523-A2 | Composition of positive photosensitive resin precursor, and display device made thereof | TORAY INDUSTRIES, INC. (JP) | 2002-05-29 | — | — | EP | disclosed |
| EP-1132773-A1 | POSITIVE-TYPE PHOTOSENSITIVE POLYIMIDE PRECURSOR COMPOSITION | TORAY INDUSTRIES, INC. (JP) | 2001-09-12 | — | — | EP | disclosed |
| CN-1293216-A | Polyolefinic resin for coating silicon dioxide and its preparation method | NIPPON SHEET GLASS CO LTD (JP) | 2001-05-02 | — | — | CN | disclosed |
| EP-1094090-A2 | Silicon dioxide-coated polyolefin resin and process for its production | NIPPON SHEET GLASS CO. LTD. (JP) | 2001-04-25 | — | — | EP | disclosed |
| EP-0816404-B1 | Methods for preparing silicone-modified vinyl polymers | DOW CORNING TORAY SILICONE (JP) | 2001-01-24 | — | — | EP | disclosed |
| EP-1037112-A1 | POSITIVE PHOTOSENSITIVE RESIN PRECURSOR COMPOSITION AND PROCESS FOR PRODUCING THE SAME | TORAY INDUSTRIES, INC. (JP) | 2000-09-20 | — | — | EP | disclosed |
| US-5777052-A | Silicone modified vinyl polymers and method for the preparation thereof | DOW CORNING TORAY SLICONE CO., LTD. (JP) | 1998-07-07 | — | — | US | disclosed |
| EP-0816404-A2 | Methods for preparing silicone-modified vinyl polymers | Dow Corning Toray Silicone Company, Limited (JP) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168074-B2 | Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone polymer | PDE2A, PDE3A, PDE3B | ALDH1A1 3487/4885TSHR 1050/4885MGAM 1898/4885 |
| US-12214088-B2 | Transdermal therapeutic system for the transdermal administration of guanfacine comprising at least one additive | GUCY1A2, PDE2A, PDE3A | ALDH1A1 2210/4885TSHR 2021/4885MGAM 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.